Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01750567

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

Relapsed Chronic Lymphocytic Leukemia Clinical Trial

Official title:
A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q

Clinical Trial Summary

Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism which sensitizes tissues to insulin, inhibits hepatic gluconeogenesis, and stimulates uptake of glucose in muscle, thereby reducing fasting blood glucose and circulating levels of insulin, lowering the pro survival activity of the insulin/INSR axis, and 2) a direct, insulin-independent mechanism which activates the AMP-activated protein kinase (AMPK) pathway and leads to inhibition of the mTOR pathway. Given the investigators preliminary published data on insulin and mTOR inhibition[1] metformin is an attractive candidate for a pilot clinical trial in CLL patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01750567
Study type Interventional
Source University of Michigan Rogel Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 2012
Completion date May 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05479994 - Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Withdrawn NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Phase 1
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Recruiting NCT05805605 - Allo HSCT Using RIC and PTCy for Hematological Diseases Phase 2
Recruiting NCT05246345 - Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Recruiting NCT05828589 - A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Phase 1
Completed NCT02181478 - Intra-Osseous Co-Transplant of UCB and hMSC Early Phase 1
Active, not recruiting NCT04191187 - Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Phase 2
Active, not recruiting NCT04624633 - Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Phase 2
Recruiting NCT04305444 - Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Phase 2